GeneDx Holdings Corp. WGS
Last close
56.15
2026-10-23
Market cap
$1.67B
2026-06-30 share count
52-week range
32.21 - 170.87
Valuation FY2025 figures against the last close
P/S3.9x
P/E—
P/FCF117.4x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.73
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M | $179.3M | $196.2M | — |
| Cost of revenue | $129.4M | $111.1M | $112.6M | $261.4M | $228.8M | $175.3M | $113.4M | — |
| Gross profit | $298.2M | $194.4M | $90.0M | -$26.8M | -$16.6M | $4.0M | $82.8M | — |
| R&D | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M | $72.7M | $34.9M | — |
| SG&A | $150.8M | $104.5M | $139.0M | $216.2M | $206.0M | $100.7M | $29.5M | — |
| Operating income | -$13.1M | -$23.2M | -$180.6M | -$667.7M | -$446.1M | -$242.0M | -$30.4M | — |
| Interest expense | — | — | $1.1M | $666.0K | $2.8M | $2.5M | $783.0K | — |
| Pre-tax income | -$21.1M | -$52.6M | -$176.7M | -$598.0M | -$245.4M | -$241.3M | -$29.7M | — |
| Income tax | $116.0K | $343.0K | $926.0K | $49.1M | $0 | $0 | $0 | — |
| Net income | -$21.0M | -$52.3M | -$175.8M | -$549.0M | -$245.4M | -$241.3M | -$29.7M | — |
| EPS, basic | -0.73 | -1.94 | -7.23 | -53.63 | -2.27 | -47,036.00 | -264,056.00 | — |
| EPS, diluted | -0.73 | -1.94 | -7.23 | -53.63 | -2.27 | -47,036.00 | -264,056.00 | — |
| Shares, diluted (wtd. avg.) | 28.6M | 26.9M | 24.3M | 10.2M | 108.1M | 5,131 | 124 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $105.0M | $85.2M | $100.7M | $138.3M | $401.5M | $108.1M | $115.0M | $1.2M |
| Short-term investments | $66.3M | $56.0M | $30.5M | $0 | — | — | — | — |
| Receivables | $74.4M | $37.6M | — | $42.6M | $26.5M | $32.0M | — | — |
| Inventory | $14.0M | $10.7M | $8.8M | $13.7M | $33.5M | $25.0M | — | — |
| Total current assets | $268.3M | $198.0M | $182.3M | $212.6M | $483.5M | $174.1M | — | — |
| Property, plant and equipment | $45.7M | $32.9M | $32.5M | $51.5M | $62.7M | $63.1M | — | — |
| Goodwill | $13.5M | $0 | — | — | $0 | $0 | — | — |
| Other intangibles | $168.5M | $158.6M | $172.6M | $186.7M | $0 | — | — | — |
| Total assets | $523.7M | $419.4M | $418.8M | $490.9M | $554.1M | $251.6M | — | — |
| Accounts payable | $2.5M | $8.0M | $10.2M | $46.0M | $44.7M | $26.7M | — | — |
| Short-term debt | $4.5M | $1.2M | $497.0K | $4.8M | $0 | $1.8M | — | — |
| Total current liabilities | $108.9M | $54.8M | $58.8M | $144.3M | $101.3M | $73.4M | — | — |
| Long-term debt | $48.2M | $51.9M | $52.7M | $6.2M | $11.0M | $19.0M | — | — |
| Total liabilities | $215.5M | $174.1M | $190.7M | $237.2M | $166.0M | $247.3M | — | — |
| Retained earnings | -$1.37B | -$1.35B | -$1.30B | -$1.12B | -$575.4M | -$330.1M | — | — |
| Total equity | $308.2M | $245.2M | $228.0M | $253.7M | $388.1M | -$330.1M | -$88.7M | -$56.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M | -$93.1M | -$18.7M | — |
| Depreciation and amortisation | $9.6M | $7.9M | $19.7M | $50.0M | $21.8M | $11.7M | $6.4M | — |
| Stock-based compensation | $32.2M | $9.1M | -$326.0K | $42.0M | $219.4M | $120.2M | $5.5M | — |
| Capital expenditure | $19.0M | $5.5M | $5.2M | $7.2M | $9.4M | $24.1M | $11.9M | — |
| Investing cash flow | -$61.5M | -$30.1M | -$43.7M | -$141.3M | -$20.8M | -$32.0M | -$15.5M | — |
| Financing cash flow | $48.0M | $44.2M | $186.2M | $197.3M | $493.7M | $129.1M | $148.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001818331-26-000030.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $196.2M | $179.3M | $212.2M | $234.7M | $202.6M | $305.4M | $427.5M |
| Gross profit | — | $82.8M | $4.0M | -$16.6M | -$26.8M | $90.0M | $194.4M | $298.2M |
| Net income | — | -$29.7M | -$241.3M | -$245.4M | -$549.0M | -$175.8M | -$52.3M | -$21.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.94B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.86B | 124.5x | 22.3% |
| PNTG | Pennant Group, Inc. | $1.46B | 49.9x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.32B | 62.3x | 16.3% |
| INNV | InnovAge Holding Corp. | $1.30B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.16B | — | 53.2% |
| SRTA | Strata Critical Medical, Inc. | $412.3M | 9.3x | 34.3% |
| DCGO | DocGo Inc. | $26.8M | — | -47.7% |